PDF(3972 KB)
利用CES1和DPP-IV的组织残余活性准确评估和追踪特异性肝损伤过程
Qiusha Pan, Peifang Song, Zhenhua Ni, Xingkai Qian, Anqi Wang, Liwei Zou, Yong Liu, Ping Wang, Weidong Zhang, Hong Ma, Ling Yang
工程（英文） ›› 2022, Vol. 19 ›› Issue (12) : 153-165.
PDF(3972 KB)
PDF(3972 KB)
利用CES1和DPP-IV的组织残余活性准确评估和追踪特异性肝损伤过程
Accurate Assessment and Tracking the Process of Liver-Specific Injury by the Residual Tissue Activity of Carboxylesterase 1 and Dipeptidyl Peptidase 4
准确评估和追踪特异性肝损伤及其进程仍然是当前生物标志物研究中的一大挑战。本研究建立了一种回顾追溯验证方法，用以表征α-萘异硫氰酸酯（ANIT）诱导的特异性肝脏胆管损伤后血清标志物与组织标志物之间的互动关系。研究发现羧酸酯酶1（CES1）作为肝内标志物和二肽基肽酶4（DPP-IV）作为肝外标志物可反映肝脏损伤的不同病理生理状态。CES1 和DPP-IV 水平可甄别肝损伤本身和炎症损伤之间的差异。相比之下，常规血清学标志物碱性磷酸酶（ALP）、丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）在ANIT诱导损伤后血清和组织水平同时升高，胆汁中胆汁酸水平下降，血清中胆汁酸水平升高，肝内组织中胆汁酸水平升高。尽管血清与组织中γ-谷氨酰基转肽酶（γ-GT）升降水平的变化方向相反，但其持续时间远短于CES1，并迅速恢复到正常水平。在上述生物标志物中，只有CES1 能够明确排除炎症干扰下的肝细胞损伤。CES1 还能准确评估熊去氧胆酸（UDCA；单成分药物）和清肺排毒汤（QFPDD；多组分药物）的抗胆汁淤积作用。研究发现QFPDD和UDCA均能减轻ANIT 诱导的肝损伤。UDCA在促进胆汁排泄方面的效果更强，但其抗损伤和抗炎作用相对较弱，而QFPDD在阻断肝脏炎症和修复肝损伤方面更有效。本文数据强调了联合使用CES1（作为肝内肝损伤标志物）和DPP-IV（作为肝外炎症作用标志物）可准确评估和追踪特异性肝损伤，并可区分肝损伤和炎症性肝损伤的差异。
Accurately assessing and tracking the progression of liver-specific injury remains a major challenge in the field of biomarker research. Here, we took a retrospective validation approach built on the mutuality between serum and tissue biomarkers to characterize the liver-specific damage of bile duct cells caused by a-naphthyl isothiocyanate (ANIT). We found that carboxylesterase 1 (CES1), as an intrahepatic marker, and dipeptidyl peptidase 4 (DPP-IV), as an extrahepatic marker, can reflect the different pathophysiologies of liver injury. Levels of CES1 and DPP-IV can be used to identify liver damage itself and the inflammatory state, respectively. While the levels of the conventional serological biomarkers alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were all concomitantly elevated in serum and tissues after ANIT-induced injury, the levels of bile acids decreased in bile, increased in serum, and ascended in intrahepatic tissue. Although the level of γ-glutamyl transpeptidase (γ-GT) changed in an opposite direction, the duration was much shorter than that of CES1 and was quickly restored to normal levels. Therefore, among the abovementioned biomarkers, only CES1 made it possible to specifically determine whether the liver cells were destroyed or damaged without interference from inflammation. CES1 also enabled accurate assessment of the anti-cholestasis effects of ursodeoxycholic acid (UDCA; single component) and Qing Fei Pai Du Decoction (QFPDD; multicomponent). We found that both QFPDD and UDCA attenuated ANIT-induced liver damage. UDCA was more potent in promoting bile excretion but showed relatively weaker anti-injury and antiinflammatory effects than QFPDD, whereas QFPDD was more effective in blocking liver inflammation and repairing liver damage. Our data highlights the potential of the combined use of CES1 (as an intrahepatic marker of liver damage) and DPP-IV (as an extrahepatic marker of inflammation) for the accurate evaluation and tracking of liver-specific injury–an application that allows for the differentiation of liver damage and inflammatory liver injury.
羧酸酯酶1 / 二肽基肽酶4 / 特异性肝脏损伤 / 标志物来源追溯
Carboxylesterase 1 / Dipeptidyl peptidase 4 / Liver injury / Validation tracking
| [1] |
Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008;245(3):194–205.
|
| [2] |
Den Bakker MA. Is histopathology still the gold standard? Ned Tijdschr Geneeskd 2017;160:D981. Dutch.
|
| [3] |
Fu S, Wu D, Jiang W, Li J, Long J, Jia C, et al. Molecular biomarkers in druginduced liver injury: challenges and future perspectives. Front Pharmacol 2020;10:1667.
|
| [4] |
Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24(8):971–83.
|
| [5] |
Ferrigno A, Palladini G, Bianchi A, Rizzo V, Di Pasqua LG, Perlini S, et al. Lobespecific heterogeneity in asymmetric dimethylarginine and matrix metalloproteinase levels in a rat model of obstructive cholestasis. BioMed Res Int 2014;2014:1–8.
|
| [6] |
Graham C, Chooniedass R, Stefura WP, Lotoski L, Lopez P, Befus AD, et al. Stability of pro- and anti-inflammatory immune biomarkers for human cohort studies. J Transl Med 2017;15(1):53.
|
| [7] |
Na K, Lee EY, Lee HJ, Kim KY, Lee H, Jeong SK, et al. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. Proteomics 2009;9(16):3989–99.
|
| [8] |
Perner F, Gyuris T, Rákóczy G, Sárváry E, Görög D, Szalay F, et al. Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: experimental and clinical evidence. J Lab Clin Med 1999;134(1):56–67.
|
| [9] |
Zou LW, Wang P, Qian XK, Feng L, Yu Y, Wang DD, et al. A highly specific ratiometric two-photon fluorescent probe to detect dipeptidyl peptidase IV in plasma and living systems. Biosens Bioelectron 2017;90:283–9.
|
| [10] |
López-Riera M, Conde I, Castell JV, Jover R. A novel microRNA signature for cholestatic drugs in human hepatocytes and its translation into novel circulating biomarkers for drug-induced liver injury patients. Toxicol Sci 2020;173(2):229–43.
|
| [11] |
Imai T, Taketani M, Shii M, Hosokawa M, Chiba K. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos 2006;34(10):1734–41.
|
| [12] |
Wang DD, Zou LW, Jin Q, Guan XQ, Yu Y, Zhu YD, et al. Bioluminescent sensor reveals that carboxylesterase 1a is a novel endoplasmic reticulumderived serologic indicator for hepatocyte injury. ACS Sens 2020;5 (7):1987–95.
|
| [13] |
Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5(5):428–30.
|
| [14] |
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020;26(7):1017–32.
|
| [15] |
Sivandzadeh GR, Askari H, Safarpour AR, Ejtehadi F, Raeis-Abdollahi E, Vaez Lari A, et al. COVID-19 infection and liver injury: clinical features, biomarkers, potential mechanisms, treatment, and management challenges. World J Clin Cases 2021;9(22):6178–200.
|
| [16] |
Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver int 2020;40(5):998–1004.
|
| [17] |
Deng ML, Chen YJ, Yang ML, Liu YW, Chen H, Tang XQ, et al. COVID-19 combined with liver injury: current challenges and management. World J Clin Cases 2021;9(15):3487–97.
|
| [18] |
Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: abnormal liver function tests. J Hepatol 2020;73(3):566–74.
|
| [19] |
Maremanda KP, Sundar IK, Li D, Rahman I. Age-dependent assessment of genes involved in cellular senescence, telomere, and mitochondrial pathways in human lung tissue of smokers, COPD, and IPF: associations with SARS-CoV-2 COVID-19 ACE2–TMPRSS2–Furin–DPP4 axis. Front Pharmacol 2020;11:584637.
|
| [20] |
Bassendine MF, Bridge SH, McCaughan GW, Gorrell MD. COVID-19 and comorbidities: a role for dipeptidyl peptidase 4 (DPP4) in disease severity? J Diabetes 2020;12(9):649–58.
|
| [21] |
Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol 2020;57(7):779–83.
|
| [22] |
Zhong LLD, Lam WC, Yang W, Chan KW, Sze SCW, Miao J, et al. Potential targets for treatment of coronavirus disease 2019 (COVID-19): a review of Qing-FeiPai-Du-Tang and its major herbs. Am J Chin Med 2020;48(05):1051–71.
|
| [23] |
Xu F, Hou T, Shen A, Jin H, Xiao Y, Yu W, et al. Mechanism deconvolution of Qing Fei Pai Du decoction for treatment of coronavirus disease 2019 (COVID19) by label-free integrative pharmacology assays. J Ethnopharmacol 2021;280:114488.
|
| [24] |
Wu XV, Dong Y, Chi Y, Yu M, Wang W. Traditional Chinese medicine as a complementary therapy in combat with COVID-19—a review of evidencebased research and clinical practice. J Adv Nurs 2021;77(4):1635–44.
|
| [25] |
Xu X, Xia J, Zhao S, Wang Q, Ge G, Xu F, et al. Qing-Fei-Pai-Du decoction and wogonoside exert anti-inflammatory action through down-regulating USP14 to promote the degradation of activating transcription factor 2. FASEB J 2021;35(9):e21870.
|
| [26] |
Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology 2011;53(4):1377–87.
|
| [27] |
Dietrich CG, Ottenhoff R, de Waart DR, Oude Elferink RP. Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 2001;167(1):73–81.
|
| [28] |
Kossor DC, Goldstein RS, Ngo W, DeNicola DB, Leonard TB, Dulik DM, et al. Biliary epithelial cell proliferation following alpha-naphthylisothiocyanate (ANIT) treatment: relationship to bile duct obstruction. Fundam Appl Toxicol 1995;26(1):51–62.
|
| [29] |
Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012;56(5):1751–9.
|
| [30] |
Cullen JM, Faiola B, Melich DH, Peterson RA, Jordan HL, Kimbrough CL, et al. Acute a-naphthylisothiocyanate-induced liver toxicity in germfree and conventional male rats. Toxicol Pathol 2016;44(7):987–97.
|
| [31] |
Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer 2016;139 (8):1764–75.
|
| [32] |
Xie G, Wang Y, Wang X, Zhao A, Chen T, Ni Y, et al. Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS. J Proteome Res 2015;14 (2):850–9.
|
| [33] |
Maronpot RR, Yoshizawa K, Nyska A, Harada T, Flake G, Mueller G, et al. Hepatic enzyme induction histopathology. Toxicol Pathol 2010;38(5):776–95.
|
| [34] |
Tu C, Gao Y, Song D, Niu M, Ma R, Zhou M, et al. Screening for susceptibilityrelated biomarkers of diclofenac-induced liver injury in rats using metabolomics. Front Pharmacol 2021;12:693928.
|
| [35] |
Apica BS, Lee WM. Drug-induced liver injury. Pathobiol Hum Dis 2014;127 (6):1825–37.
|
| [36] |
Her L, Zhu HJ. Carboxylesterase 1 and precision pharmacotherapy: pharmacogenetics and nongenetic regulators. Drug Metab Dispos 2020;48 (3):230–44.
|
| [37] |
Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, et al. Effects of shosaiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999;29(1):149–60.
|
| [38] |
Zhou YX, Qiu YQ, Xu LQ, Guo J, Li LJ. Xiao-Chai-Hu Tang in treating model mice with D-galactosamine-induced liver injury. Afr J Tradit Complement Altern Med 2012;9(3):405–11.
|
| [39] |
Takahashi Y, Soejima Y, Kumagai A, Watanabe M, Uozaki H, Fukusato T, et al. Inhibitory effects of Japanese herbal medicines sho-saiko-to and juzen-taihoto on nonalcoholic steatohepatitis in mice. PLoS ONE 2014;9(1):e87279.
|
| [40] |
Chen MH, Chen JC, Tsai CC, Wang WC, Chang DC, Lin CC, et al. Sho-saiko-to prevents liver fibrosis induced by bile duct ligation in rats. Am J Chin Med 2004;32(2):195–207.
|
| [41] |
Wang H, Fang ZZ, Meng R, Cao YF, Tanaka N, Krausz KW, et al. Glycyrrhizin and glycyrrhetinic acid inhibits alpha-naphthyl isothiocyanate-induced liver injury and bile acid cycle disruption. Toxicology 2017;386:133–42.
|
| [42] |
Röhrl C, Eigner K, Fruhwürth S, Stangl H, Kanzaki M. Bile acids reduce endocytosis of high-density lipoprotein (HDL) in HepG2 cells. PLoS ONE 2014;9(7):e102026.
|
| [43] |
Oizumi K, Sekine S, Fukagai M, Susukida T, Ito K. Identification of bile acids responsible for inhibiting the bile salt export pump, leading to bile acid accumulation and cell toxicity in rat hepatocytes. J Pharm Sci 2017;106 (9):2412–9.
|
/
| 〈 |
|
〉 |
